Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 3-armed trial	256 people with suspected PCP; 181 people with confirmed diagnoses (only those with confirmed diagnoses were evaluated further)	Rate of adverse effects requiring a change in dose or treatment 19/59 (32%) with trimethoprim–dapsone 23/64 (36%) with TMP–SMX	OR 0.6 95% CI 0.2 to 1.3 P = 0.2		Not significant
RCT	60 people with a first episode of confirmed PCP and PaO2 >60 mmHg on room air	Rate of major adverse effects (unspecified) 9/30 (30%) with trimethoprim–dapsone 17/30 (57%) with TMP–SMX	P <0.03	Effect size not calculated	trimethoprim–dapsone